Weiyuan Bio Completes Tens of Millions RMB Seed Funding Round to Advance into Synthetic Biology

VBInsight has learned at the earliest opportunity that,Recently,Hangzhou Weiyuan Biotechnology Co., Ltd. Successfully Completes Seed Round Financing of Tens of Millions of Yuan, with Participation from Dajing Venture Capital, Oufang Angel, Xinghua Dingli, and Zhenshi Capital

▲ Weiyuan Biotechnology

Hangzhou Weiyuan Biotechnology Co., Ltd. was founded in early 2023 by young entrepreneurs with successful startup experience,Professional investment institutions such as Dajing Venture Capital, Oufang Angel, Xinghua Dingli, and Zhenshi Capital participated in the entire process of Weiyuan Biotechnology, from conception to implementation.The company's R&D center is located in Binjiang District, Hangzhou, covering an area of 2,500 square meters. After several months of meticulous preparation and rapid advancement, it was officially put into operation recently.

Hangzhou Weiyuan Biotechnology Co., Ltd. is a synthetic biology company that leverages intelligent enzyme evolution and high-throughput strain screening as its technological engines, employs “Compendium of Materia Medica”-style precise analysis and intelligent prediction as its technical methods, and delivers production capacity through the efficient manufacturing of chiral compounds, enhanced extraction of bioactive natural products, and rapid construction of recombinant cell factories.

▲     Weiyuan Biotech Enzymatic Technology Platform

Following the completion of its seed funding round, Weiyuan Biotechnology rapidly assembled a team comprising dozens of senior scientists and domain-specific experts dedicated to advancing innovation and pursuing ambitious goals. The company is committed to building a large-scale R&D and industrialization service platform for synthetic biology. By engaging in deep collaborations with clients, Weiyuan Biotechnology jointly constructs precise and efficient enzymatic catalysis systems and recombinant cell factories, co-developing chiral compounds and active natural products that offer revolutionary advantages in safety, environmental sustainability, and cost-effectiveness.

Regarding this financing round,Wu Yan, Founder of Hangzhou Weiyuan Biotechnology Co., Ltd.We sincerely thank all investors for their support and trust. He stated, “With the impetus of capital, Weiyuan Biotechnology has leveraged its unique advantages—rooted in successful entrepreneurial experience and the deep integration of biology and chemistry—to rapidly establish a core team and R&D center, and to reach agreements with multiple key clients for the joint development of blockbuster products. We are confident that, driven by the combined forces of our team, capital partners, and clients, Weiyuan Biotechnology will achieve snowballing rapid growth, swiftly secure a leading position in the industry amidst the innovation wave of synthetic biology, and emerge as an influential emerging enterprise in the field of synthetic biology.”

The investment institutions participating in this financing round have witnessed Weiyuan Biotechnology’s evolution from an initial conceptual prototype into a company that now combines strength with vision. Their deep understanding of Weiyuan and trust in its founder, Wu Yan, have instilled in them strong confidence in the company’s future development.

Zhu Guoying, General Manager of Dajing Venture CapitalShe believes that the key to investment lies in backing people, and the crux of a team depends on its leader. “In Wu Yan, founder of Weiyuan, I see the hallmark pragmatism and truth-seeking spirit of Zhejiang University alumni. I am confident that the professional and efficient team he leads will surely carve out its own niche in the burgeoning era of synthetic biology.”

Liu Jianbin, Founder of Oufang AngelIt was stated that Wu Yan graduated with a major in Biological Engineering from the Mixed Class at Zhejiang University, has dedicated 20 years to the biomedical and pharmaceutical sector, and previously founded a company that was successfully acquired. Today, as synthetic biology gains momentum and the industry enters a fast-track development phase, we are confident that Wu Yan will lead Hangzhou Weiyuan Biotechnology Co., Ltd. to achieve outstanding results in this biotechnological revolution.

Yang Zhenhuan, Investment Director at Xinghua Dingli“Synthetic biology has a wide range of applications and has demonstrated rapid growth in recent years, particularly in areas such as peptide synthesis and recombinant enzyme production. Mr. Wu brings over 20 years of experience in biomedical R&D, pilot-scale testing, and industrialization. The company’s team possesses extensive capabilities in biotransformation and chemical synthesis. We are confident that the founding team led by Mr. Wu will leverage its accumulated expertise to achieve even greater success in this field.”

Dr. An Kai, Head of Biopharmaceutical Investments at Zhenshi Capital“Synthetic biology has ushered in the era of biomanufacturing, with its industrialization spanning numerous sectors including pharmaceuticals, chemicals, agriculture, and cosmetics. Hangzhou Weiyuan Biotechnology Co., Ltd. has mastered core technologies, established an excellent team structure, and stands as a rare enterprise in China’s synthetic biology landscape that places equal emphasis on both platform development and product innovation. We are honored to partner with Weiyuan Biotechnology and look forward to growing alongside the company. We anticipate that Weiyuan Biotechnology will bring more products to market in the future, transforming our lives and contributing to the grand blueprint of carbon neutrality.”

Zhejiang Dajing Venture Capital Co., Ltd. was established in 2001. Over the years, it has been dedicated to venture capital investment, financial advisory and IPO planning, corporate asset restructuring, and other services, providing capital value-added services to domestic enterprises. The company has received numerous honors, including “Excellent Venture Capital Institution in China,” “Excellent Venture Capital Project in China,” “Best Investment Institution for Zhejiang Merchants,” and “Top Ten Local Venture Capital Institutions in Zhejiang.” Rooted in the century-old “Qiu Shi” (Seeking Truth) spirit of Zhejiang University, the company adheres to its corporate philosophy of “Wisdom, Dedication, and Achievement.” Since its inception, the company has successfully invested in and facilitated the public listing of several companies, including Transfar Zhilian (002010), Insigma Technology (600797), Crystal-Optech (002273), Do-Fluoride Chemicals (002407), Jingu Shares (002488), and Jingsheng Electromechanical (300316).

Oufang Angels focuses on serving and investing in startups founded by Zhejiang University alumni, faculty, and students, dedicated to supporting them in becoming business leaders who are “public-spirited, loyal, resolute, capable of shouldering great responsibilities, leading societal trends, and shaping the nation’s destiny.” Oufang’s mission is to help purpose-driven members of the Zhejiang University community undertake meaningful endeavors. Its vision is to link Zhejiang University alumni through “Ou” (lotus root) and uphold the spirit of “Seeking Truth” through “Fang” (boat).

The Oufang team has invested in over 80 startups founded by Zhejiang University alumni, including Bangtang Technology, Tangji Medical, Xingse, Paraca, Maquan Information, Shenshi Technology, Shuangshen Information, Dianke IoT, Duoyi Technology, Ruiweishi Technology, Diwei'er Space Technology, Shiguang Semiconductor, Qingta Technology, Aoxin Technology, Wandian Travel, Yimu Visual, Chaoguang Micro, Suzhitong Technology, and Zaizao Regeneration in the technology sector; and Tuoxi Technology, Sanxiang Technology, Libei Hydraulics, Yingchuang New Materials, Himalaya Technology, Chitu Technology, Haichuan Electric, and Jingbao New Energy in the intelligent manufacturing sector.

Xinghua Dingli was founded in 2022 as an emerging professional venture capital firm specializing in biopharmaceuticals, new energy, and semiconductors. It is dedicated to identifying and supporting outstanding entrepreneurs who consistently create value. The core team possesses extensive venture capital experience, having invested in over 50 companies with a total investment exceeding RMB 1.5 billion. A significant number of its early-stage portfolio companies have grown into leading enterprises within their respective niche sectors. Currently, Xinghua Dingli manages funds totaling over RMB 500 million and has invested in more than 15 high-quality enterprises. It was honored as the “2022 Zhejiang Emerging Venture Capital Institution.”

Hangzhou Silicon Valley Zhenshi Asset Management Co., Ltd. is an equity investment firm specializing in investments within high-tech sectors. Headquartered in Binjiang District, Hangzhou, the company has established a strategic presence across key scientific and technological innovation hubs in the Yangtze River Delta, Pearl River Delta, as well as central and southwestern China. With years of deep expertise in new energy, new materials, intelligent equipment, and biopharmaceuticals, the team is dedicated to facilitating the commercialization of cutting-edge scientific research by top-tier scientists and helping enterprises or teams with core competencies rapidly establish industry-leading advantages. The company has consistently tracked and incubated projects leveraging the distinctive academic strengths of prestigious research institutions such as Zhejiang University, the University of Science and Technology of China, and Central South University, having invested in more than 20 high-growth technology enterprises to date.